**Supplementary Table 1**

**Comparisons between the current guideline and the Chinese prevention guidelines in 2011 and 2017**

|  |  |  |  |
| --- | --- | --- | --- |
| **Items** | Chinese guidelines for prevention of cardiovascular diseases, 2011[6] | Chinese guidelines for the prevention of cardiovascular diseases, 2017[7] | Chinese guideline on the primary prevention of cardiovascular diseases, 2020 |
| **Writing committee** | Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology | Chinese guidelines for prevention of cardiovascular diseases (2017) writing group, Editorial Board of Chinese Journal of Cardiology | Chinese Society of Cardiology of Chinese Medical Association and other 3 associations |
| **Review of evidence** | Experts’ consensus | Experts’ consensus | Systematic review |
| **Level of evidence** | Not included | Not included | A, B, and C |
| **Class of recommendation** | Not included | Not included | Ⅰ, Ⅱa, Ⅱb, and Ⅲ |
| **Risk assessment** | Risk assessment score and chart for ischemic CVD developed based on a Chinese cohort study | Risk assessment tool for ASCVD that was developed based on a Chinese cohort study | Risk assessment tool for both ASCVD and total CVD based on a Chinese cohort study |
| **Lifestyle intervention** | Smoking, diet, obesity, and physical activity | Smoking, salt intake, alcohol consumption, physical activity, and diet | Diet, physical activity, body weight, smoking, alcohol consumption, sleeping, and mental health |
| **Risk factor control** | Management of blood pressure, lipids, and glucose | Management of blood pressure, lipids, glucose, and the use of aspirin | Management of blood pressure, lipids, glucose, and the use of aspirin |
| **Control of other comorbidities** | Chronic kidney diseases, metabolic syndrome, inflammation, coagulation factors, genetic factors, and social psychological factors | Stroke prevention in patients with atrial fibrillation | Not included |
| **Secondary prevention** | Management of blood pressure and glucose and antithrombotic therapy in patients with CVD | Secondary prevention of stroke and coronary heart disease | Not included |

ASCVD: Atherosclerotic cardiovascular disease; CVD: Cardiovascular disease.